Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Clinical Case 2: 59-Year-Old Woman With R/R MM

February 4th 2022

Experts in hematology-oncology review the case of a 59-year-old woman with relapsed/refractory multiple myeloma and discuss their thoughts on the given treatment approach.

Selecting the Appropriate Treatment Regimen and Assessing Response at First Relapse in Myeloma

February 4th 2022

Sagar Lonial, MD; Joshua Richter, MD; and Ola Landgren, MD, PhD, comment on the selection of the appropriate treatment regimen at first relapse, including CD38-based, non-CD38–based and non-PI–based treatment regimens for multiple myeloma, and discuss their approach to assessing treatment response.

ASH 2021: Key Takeaways for Clinical Practice in Multiple Myeloma

February 4th 2022

Closing out his discussion on the ASH 2021 meeting, Saad Usmani, MD, shares key takeaways for clinical practice in multiple myeloma.

ASH 2021: Additional Highlights in Multiple Myeloma

February 4th 2022

Saad Usmani, MD, shares his excitement for additional clinical trial data in multiple myeloma presented at the ASH 2021 annual meeting.

Adding Venetoclax to Daratumumab and Dexamethasone in RRMM

February 4th 2022

In relapsed/refractory multiple myeloma, a recent study tested the addition of venetoclax to daratumumab and dexamethasone.

Relapsed/Refractory MM: Results From the BELLINI Study

February 4th 2022

Insight on the BELLINI study, which added venetoclax to bortezomib and dexamethasone for patients with relapsed/refractory multiple myeloma.

Daratumumab in NDMM: Subcutaneous vs IV Formulation

February 4th 2022

Closing out his discussion on newly diagnosed multiple myeloma, Saad Usmani, MD, considers the approval and use of subcutaneous daratumumab.

Triplet or Quadruplet Therapy in Transplant-Ineligible NDMM

February 4th 2022

In the context of transplant-ineligible newly diagnosed multiple myeloma, Saad Usmani, MD, considers the role of triplet versus quadruplet therapy.

Transplant-Eligible NDMM: Results From the MASTER Study

February 4th 2022

Expert perspective on results from the MASTER study analyzing daratumumab in combination with KRd in transplant-eligible newly diagnosed multiple myeloma.

Transplant-Eligible NDMM: Updated Results of the GRIFFIN Study

February 4th 2022

Updated results from the GRIFFIN study, which combined daratumumab with RVd in patients with transplant-eligible newly diagnosed multiple myeloma.

Dr. Usmani on Emerging Treatment Strategies in Late Relapsed Multiple Myeloma

February 2nd 2022

Saad Z. Usmani, MD, MBA, FACP, discusses emerging treatment strategies in late relapsed multiple myeloma.

European Approval Sought for Teclistamab in Relapsed/Refractory Multiple Myeloma

February 1st 2022

A marketing authorization application has been submitted to the European Medicines Agency seeking the approval of teclistamab for the treatment of patients with relapsed or refractory multiple myeloma.

IKEMA Study in R/R Multiple Myeloma

January 28th 2022

Ola Landgren, MD, PhD, reviews the results and clinical implications of the IKEMA study for patients with relapsed/refractory multiple myeloma.

Updates From the CANDOR Study in R/R Multiple Myeloma

January 28th 2022

Katja Weisel, MD, leads a review of the study design and updated efficacy and safety results of the phase 3 CANDOR study for patients with relapsed/refractory multiple myeloma.

Addition of Isatuximab to RVd as Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma (GMMG-HD7)

January 27th 2022

Expert hematologist/oncologist Joseph Mikhael, MD, shares insight on the phase III GMMG-HD7 trial, which added isatuximab to RVd in the setting of newly diagnosed, transplant-eligible multiple myeloma.

Key Takeaways From the ASH 2021 Meeting on Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

January 25th 2022

Closing out her discussion on the management of newly diagnosed and relapsed/refractory multiple myeloma, Amrita Y. Krishnan, MD, shares key takeaways from the ASH 2021 Annual Meeting.

How Will Bispecific Antibodies Fit Into the Multiple Myeloma Treatment Paradigm?

January 25th 2022

Amrita Y. Krishnan, MD, considers where bispecific antibodies will fit into the multiple myeloma treatment paradigms as single-agent or combination therapy.

A Role for Bispecific Antibodies in R/R MM: Data From MonumenTAL-1 and MajesTEC-1 Studies

January 25th 2022

Insight on results from the MonumenTAL-1 and MajesTEC-1 studies, which evaluated bispecific antibodies in patients with relapsed/refractory multiple myeloma.

Treatment Options for Patients With MM at First Relapse

January 25th 2022

Expert perspective on the management of multiple myeloma at first relapse in the context of recent clinical data from the ASH 2021 Annual Meeting.

Subcutaneous Daratumumab Plus Kd Is a “Gamechanger” for Patients With Multiple Myeloma

January 24th 2022

Ajai Chari, MD, reviews the takeaways from the PLEIADES trial and its comparability with the CANDOR trial, and how a subcutaneous formulation of a daratumumab combination became a pivotal player in the treatment enhancement for patients with relapsed or refractory multiple myeloma.